Komori
Takamisawa (5283) · FactAdvanced

Research and Development Expenditure

First written in FY2018-Q1. 17 of 25 entries say "Restated". Latest entry: FY2026.

25entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2018-Q1 – FY2020-Q2RestatedFY2022-Q2 – FY2023-Q3OtherFY2024-Q2 – FY2026-H12017: 12018: 320182019: 420192020: 320202021: 220212022: 320222023: 320232024: 220242025: 220252026: 22026
Same theme, other companies
Continuation of R&D activities with no change in statusA theme 192 companies write about · 0 as a headwind · 181 as a tailwind

45 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 192 companies compared. The sentences above are computed from all 192.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「The total research and development expenditure incurred by the Group during the consolidated fiscal year was ¥76 million.」

    Research and development expenses increased from ¥60 million in the previous fiscal year to ¥76 million, and achievements including a higher Locacon replacement rate and the successful mass production of Rakuraku Block are stated.
  2. FY2026-H1Higher R&D Expenses for the First HalfAnnual report

    「The Group's total research and development expenditure for the interim consolidated accounting period was ¥41 million. There were no material changes in the status of the Group's research and development activities during the interim consolidated accounting period.」

    Research and development expenditure for the first half was ¥41 million, up from ¥30 million in the same period of the previous year. It also states that there were no material changes in the status of research and development activities.
  3. FY2025R&D expenses decreased, while development of Rokakon continuedAnnual report

    「The total research and development expenditure incurred by the Group during the consolidated fiscal year was ¥60 million.」

    Research and development expenditure decreased from ¥76 million in the previous fiscal year to ¥60 million, while the description includes specific results such as development and branding of Rokakon.
  4. FY2025-H1Decline in R&D expenditure for the interim periodAnnual report

    「The Group's total research and development expenditure for the interim consolidated accounting period was ¥30 million. There were no material changes in the status of the Group's research and development activities during the interim consolidated accounting period.」

    Research and development expenditure for the first half was ¥30 million, down from ¥38 million in the same period of the previous year, while it states that there were no material changes in the status of research and development activities.
  5. FY2024-Q3RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated third-quarter period was ¥54 million. There were no material changes in the status of the Group's research and development activities during the cumulative consolidated third-quarter period.」

    It states that research and development expenditure for the cumulative third-quarter period was ¥54 million and that there were no material changes in the status of research and development activities.
  6. FY2024-Q2RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated second-quarter period was ¥38 million. There were no material changes in the status of the Group's research and development activities during the cumulative consolidated second-quarter period.」

    Research and development expenditure for the cumulative second-quarter period was ¥38 million, and it states that there were no material changes in the status of research and development activities.
  7. FY2023AdvancedAnnual report

    「The total research and development expenditure incurred by the Group during the consolidated fiscal year was ¥76 million.」

    Research and development expenditure increased from ¥66 million in the previous consolidated fiscal year to ¥76 million, and the description includes development of new products using improved CV Blocks and mechanical joints.
  8. FY2023-Q3RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated third-quarter period was ¥55 million. There were no material changes in the status of the Group's research and development activities during the cumulative consolidated third-quarter period.」

    It states that research and development expenditure for the cumulative third-quarter period was ¥55 million and that there were no material changes in the status of research and development activities.
  9. FY2023-Q2RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated second-quarter period was ¥38 million. There were no material changes in the status of the Group's research and development activities during the cumulative consolidated second-quarter period.」

    It states that research and development expenditure for the cumulative second-quarter period was ¥38 million and that there were no material changes in the status of research and development activities.
  10. FY2023-Q1RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated first-quarter period was ¥19 million. There were no material changes in the status of the Group's research and development activities during the cumulative consolidated first-quarter period.」

    Research and development expenditure for the cumulative first-quarter period was ¥19 million, and it states that there were no material changes in the status of research and development activities.
  11. FY2022-Q3RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated third-quarter period was ¥47 million. There were no material changes in the status of the Group's research and development activities during the cumulative consolidated third-quarter period.」

    It states that research and development expenditure for the cumulative third-quarter period was ¥47 million and that there were no material changes in the status of research and development activities.
  12. FY2022-Q2RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated second-quarter period was ¥32 million. There were no material changes in the status of the Group's research and development activities during the cumulative consolidated second-quarter period.」

    It states that research and development expenditure for the cumulative second-quarter period was ¥32 million and that there were no material changes in the status of research and development activities.
  13. FY2021AdvancedAnnual report

    「The total research and development expenditure incurred by the Group during the consolidated fiscal year was ¥40 million.」

    It reports ¥40 million in research and development expenditure and describes specific research and development results, including improvements to FA-BOX and development of CV-Yaw.
  14. FY2021-Q3RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated third-quarter period was ¥38 million. There were no material changes in the status of the Group's research and development activities during the cumulative consolidated third-quarter period.」

    It states that research and development expenditure for the cumulative third-quarter period was ¥38 million and that there were no material changes in the status of research and development activities.
  15. FY2021-Q1RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated first-quarter period was ¥13 million. There were no material changes in the status of the Group's research and development activities during the cumulative consolidated first-quarter period.」

    It states that research and development expenditure for the cumulative first-quarter period was ¥13 million and that there were no material changes in the status of research and development activities.
  16. FY2020AdvancedAnnual report

    「The total research and development expenditure incurred by the Group during the consolidated fiscal year was ¥50 million.」

    Research and development expenditure increased from ¥40 million in the previous consolidated fiscal year to ¥50 million, and the description includes development results such as CV Half and NEP Arch.
  17. FY2020-Q2RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated second-quarter period was ¥22 million. There were no material changes in the status of the Group's research and development activities during the cumulative consolidated second-quarter period.」

    It states that research and development expenditure for the cumulative second-quarter period was ¥22 million and that there were no material changes in the status of research and development activities.
  18. FY2020-Q1RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated first-quarter period was ¥12 million. There were no material changes in the status of the Group's research and development activities during the cumulative consolidated first-quarter period.」

    It states that research and development expenditure for the cumulative first-quarter period was ¥12 million and that there were no material changes in the status of research and development activities.
  19. FY2019RestatedAnnual report

    「The total research and development expenditure incurred by the Group during the consolidated fiscal year was ¥40 million.」

    It describes full-year research and development expenditure of ¥40 million, as well as product development and field testing of products including Guardian II.
  20. FY2019-Q3RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated third-quarter period was ¥28 million. There were no material changes in the status of the Group's research and development activities during the cumulative consolidated third-quarter period.」

    It states that research and development expenditure for the cumulative third-quarter period was ¥28 million and that there were no material changes in the status of research and development activities.
  21. FY2019-Q2RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated second-quarter period was ¥20 million.」

    It states that research and development expenditure for the cumulative second-quarter period was ¥20 million and that there were no material changes in the status of research and development activities.
  22. FY2019-Q1RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated first-quarter period was ¥10 million.」

    It states that the Group's total research and development expenditure for the cumulative first-quarter period was ¥10 million.
  23. FY2018-Q3RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated third-quarter period was ¥34 million.」

    It states that research and development expenditure for the cumulative third-quarter period was ¥34 million.
  24. FY2018-Q2RestatedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated second-quarter period was ¥24 million.」

    It states that research and development expenditure for the cumulative second-quarter period was ¥24 million.
  25. FY2018-Q1First statedAnnual report

    「The Group's total research and development expenditure for the cumulative consolidated first-quarter period was ¥12 million.」

    It states that the Group's total research and development expenditure for the cumulative first-quarter period was ¥12 million.
Moved together

"Strengthening Sales Capabilities and Proposal-Based Sales" moved the same way as this thread, in the same document, in 4 of its 25 moves.

433333★123456
  1. ★This thread
  2. 1Strengthening Sales Capabilities and Proposal-Based Sales4×
  3. 2Development of Cost-Effective, High-Performance Products3×
  4. 3Higher Revenue and Lower Operating Profit in the First Quarter3×
  5. 4Completion of Large-Scale Construction Projects and Sluggish Public and Private Construction3×
  6. 5Guarantees of Indebtedness for Housing-Loan Customers3×
  7. 6Targets of ¥63 billion in revenue and ¥1 billion in ordinary profit for the fiscal year ending June 20203×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Takamisawa's next results are scheduled for 2026-11-06. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Research and Development Expenditure | TAKAMISAWA CO.,LTD. (5283) | Komori